Evaluation of the role of Helicobacter pylori as a promoter of gastric cancer from the viewpoint of structural chromosomal aberration

T. Ohara, J. Kasanuki, T. Morishita, N. Yamamoto, T. Shibahara, Hidekazu Suzuki, Tatsuhiro Masaoka, T. Nishizawa, T. Hibi

Research output: Contribution to journalArticle

Abstract

Aim: To examine whether Helicobacter pylori induces structural chromosomal aberrations, such as loss of heterozygosity (LOH) and microsatellite instability (MSI) in the infected gastric mucosa. Methods: Subjects were 13 patients with H. pylori-positive and 9 with H. pylori-negative gastric cancer and 20 patients with H. pylori-positive and 4 patients with H. pylori-negative chronic gastritis. Gastric mucosal tissues were endoscopically sampled from each subject. Each sample was checked for structural chromosomal aberrations (LOH and MSI) by PCR and microsatellite analysis, using a total of 31 primers corresponding to the regions containing the major genes of chromosomes 1q, 5q, 7q, 17p, 17q, 18q and 21q. Results: All tissue samples obtained from cancer-affected regions of the stomach had structural chromosomal aberrations (LOH or MSI), irrespective of H. pylori infection. The degree of structural chromosomal aberration was greater in poorly differentiated than well-differentiated adenocarcinoma. In addition, structural chromosomal aberrations were also found in a few samples obtained from the chronic atrophic gastritis group, irrespective of H. pylori infection. Conclusions: It seems unlikely that H. pylori serves as a direct promoter of gastric cancer, and H. pylori-positive chronic gastritis may not always be a precancerous state.

Original languageEnglish
Pages (from-to)111-119
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume24
Issue numberSUPPL.4
DOIs
Publication statusPublished - 2006 Dec

Fingerprint

Helicobacter pylori
Chromosome Aberrations
Stomach Neoplasms
Microsatellite Instability
Loss of Heterozygosity
Helicobacter Infections
Gastritis
Stomach
Atrophic Gastritis
Gastric Mucosa
Microsatellite Repeats
Mucous Membrane
Adenocarcinoma
Chromosomes
Polymerase Chain Reaction
Genes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Evaluation of the role of Helicobacter pylori as a promoter of gastric cancer from the viewpoint of structural chromosomal aberration. / Ohara, T.; Kasanuki, J.; Morishita, T.; Yamamoto, N.; Shibahara, T.; Suzuki, Hidekazu; Masaoka, Tatsuhiro; Nishizawa, T.; Hibi, T.

In: Alimentary Pharmacology and Therapeutics, Vol. 24, No. SUPPL.4, 12.2006, p. 111-119.

Research output: Contribution to journalArticle

Ohara, T. ; Kasanuki, J. ; Morishita, T. ; Yamamoto, N. ; Shibahara, T. ; Suzuki, Hidekazu ; Masaoka, Tatsuhiro ; Nishizawa, T. ; Hibi, T. / Evaluation of the role of Helicobacter pylori as a promoter of gastric cancer from the viewpoint of structural chromosomal aberration. In: Alimentary Pharmacology and Therapeutics. 2006 ; Vol. 24, No. SUPPL.4. pp. 111-119.
@article{6dd445421f3e4ff0a60f54963c3638f0,
title = "Evaluation of the role of Helicobacter pylori as a promoter of gastric cancer from the viewpoint of structural chromosomal aberration",
abstract = "Aim: To examine whether Helicobacter pylori induces structural chromosomal aberrations, such as loss of heterozygosity (LOH) and microsatellite instability (MSI) in the infected gastric mucosa. Methods: Subjects were 13 patients with H. pylori-positive and 9 with H. pylori-negative gastric cancer and 20 patients with H. pylori-positive and 4 patients with H. pylori-negative chronic gastritis. Gastric mucosal tissues were endoscopically sampled from each subject. Each sample was checked for structural chromosomal aberrations (LOH and MSI) by PCR and microsatellite analysis, using a total of 31 primers corresponding to the regions containing the major genes of chromosomes 1q, 5q, 7q, 17p, 17q, 18q and 21q. Results: All tissue samples obtained from cancer-affected regions of the stomach had structural chromosomal aberrations (LOH or MSI), irrespective of H. pylori infection. The degree of structural chromosomal aberration was greater in poorly differentiated than well-differentiated adenocarcinoma. In addition, structural chromosomal aberrations were also found in a few samples obtained from the chronic atrophic gastritis group, irrespective of H. pylori infection. Conclusions: It seems unlikely that H. pylori serves as a direct promoter of gastric cancer, and H. pylori-positive chronic gastritis may not always be a precancerous state.",
author = "T. Ohara and J. Kasanuki and T. Morishita and N. Yamamoto and T. Shibahara and Hidekazu Suzuki and Tatsuhiro Masaoka and T. Nishizawa and T. Hibi",
year = "2006",
month = "12",
doi = "10.1111/j.1365-2036.2006.02959.x",
language = "English",
volume = "24",
pages = "111--119",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "SUPPL.4",

}

TY - JOUR

T1 - Evaluation of the role of Helicobacter pylori as a promoter of gastric cancer from the viewpoint of structural chromosomal aberration

AU - Ohara, T.

AU - Kasanuki, J.

AU - Morishita, T.

AU - Yamamoto, N.

AU - Shibahara, T.

AU - Suzuki, Hidekazu

AU - Masaoka, Tatsuhiro

AU - Nishizawa, T.

AU - Hibi, T.

PY - 2006/12

Y1 - 2006/12

N2 - Aim: To examine whether Helicobacter pylori induces structural chromosomal aberrations, such as loss of heterozygosity (LOH) and microsatellite instability (MSI) in the infected gastric mucosa. Methods: Subjects were 13 patients with H. pylori-positive and 9 with H. pylori-negative gastric cancer and 20 patients with H. pylori-positive and 4 patients with H. pylori-negative chronic gastritis. Gastric mucosal tissues were endoscopically sampled from each subject. Each sample was checked for structural chromosomal aberrations (LOH and MSI) by PCR and microsatellite analysis, using a total of 31 primers corresponding to the regions containing the major genes of chromosomes 1q, 5q, 7q, 17p, 17q, 18q and 21q. Results: All tissue samples obtained from cancer-affected regions of the stomach had structural chromosomal aberrations (LOH or MSI), irrespective of H. pylori infection. The degree of structural chromosomal aberration was greater in poorly differentiated than well-differentiated adenocarcinoma. In addition, structural chromosomal aberrations were also found in a few samples obtained from the chronic atrophic gastritis group, irrespective of H. pylori infection. Conclusions: It seems unlikely that H. pylori serves as a direct promoter of gastric cancer, and H. pylori-positive chronic gastritis may not always be a precancerous state.

AB - Aim: To examine whether Helicobacter pylori induces structural chromosomal aberrations, such as loss of heterozygosity (LOH) and microsatellite instability (MSI) in the infected gastric mucosa. Methods: Subjects were 13 patients with H. pylori-positive and 9 with H. pylori-negative gastric cancer and 20 patients with H. pylori-positive and 4 patients with H. pylori-negative chronic gastritis. Gastric mucosal tissues were endoscopically sampled from each subject. Each sample was checked for structural chromosomal aberrations (LOH and MSI) by PCR and microsatellite analysis, using a total of 31 primers corresponding to the regions containing the major genes of chromosomes 1q, 5q, 7q, 17p, 17q, 18q and 21q. Results: All tissue samples obtained from cancer-affected regions of the stomach had structural chromosomal aberrations (LOH or MSI), irrespective of H. pylori infection. The degree of structural chromosomal aberration was greater in poorly differentiated than well-differentiated adenocarcinoma. In addition, structural chromosomal aberrations were also found in a few samples obtained from the chronic atrophic gastritis group, irrespective of H. pylori infection. Conclusions: It seems unlikely that H. pylori serves as a direct promoter of gastric cancer, and H. pylori-positive chronic gastritis may not always be a precancerous state.

UR - http://www.scopus.com/inward/record.url?scp=33846063452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846063452&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2006.02959.x

DO - 10.1111/j.1365-2036.2006.02959.x

M3 - Article

AN - SCOPUS:33846063452

VL - 24

SP - 111

EP - 119

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - SUPPL.4

ER -